Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational registry to collect standardized data from adult patients receiving routine oncology care at participating cancer centers. The study aims to gather detailed information such as baseline patient characteristics, treatments administered, and outcomes to support research and improve clinical trial participation. Patient surveys are also included to enrich the data collected. No treatments or interventions are given as part of this registry. Instead, data is gathered from patients receiving their usual cancer care. This open-ended registry will continuously collect and analyze information over time to better understand treatment patterns, safety, and effectiveness. Participants will provide informed consent and contribute data through their regular care visits and surveys. Researchers will monitor treatment effectiveness mainly by tracking the time until treatment discontinuation. The registry will regularly analyze and present the data collected. Participation may last as long as the patient is receiving treatment and contributing data, with long-term follow-up possible.
Actively Recruiting
Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.
Actively Recruiting
Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.
Actively Recruiting
Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Healthy Volunteer
Researchers are investigating how adults can use the EcoExposure14 platform for at-home urine sample collection, preparation, and smartphone imaging. This observational study focuses on understanding whether participants can successfully capture and upload urine sample images using a smartphone app, and it examines the consistency of image quality and participant adherence over about 12 weeks. The study aims to support product development and workflow validation rather than provide clinical diagnoses or treatments. Participants will follow a fully remote process where they collect and prepare fresh urine samples at home according to instructions. They will take guided photographs of these samples using their own smartphones and upload the images with brief feedback through the TrialKit app. Sampling occurs at multiple scheduled timepoints at baseline Day 0, daily between Days 7 and 14 for an intensive short-term evaluation, and then on Days 21, 28, 42, 56, 70, and 84. There is an optional step where participants may add a small reference solution to one sample for technical evaluation only. During the approximately 12-week study, participants will complete electronic consent and an intake questionnaire. Researchers will monitor adherence, image quality, and usability of the workflow. The study measures how well participants complete scheduled visits and provide quality images, as well as the variability of optical signals in daily samples. No clinical decisions are made, and the results aim to improve product features and assay calibration.
Actively Recruiting
This research study focuses on both adult and pediatric participants diagnosed with Chronic Granulomatous Disease CGD. The main goal is to understand how common specific antibodies and inflammatory cytokines are in people living with CGD by measuring these markers in their blood. Participants will have blood samples collected to measure levels of adenovirus-specific antibodies and inflammatory cytokines. This is an observational study, meaning no treatments are given instead, the study observes and records these blood markers to characterize their prevalence in this patient group. During the study, participants will provide blood samples for laboratory analysis of antibody titers and cytokine levels. The main outcomes measured include total adenoviral-specific antibody levels and neutralizing antibody levels, along with inflammatory cytokine concentrations. The study is expected to be completed by December 2026.
Actively Recruiting
Researchers are building a prospective group of patients with locally advanced or metastatic non-small cell lung cancer NSCLC who have common EGFR mutations, specifically EGFR exon 19del or exon 21 L858R. The study focuses on patients diagnosed on or after January 1, 2024, and aims to collect standardized data at key points before treatment starts, during treatment, and when treatment ends. The main goal is to observe real-world progression-free survival among those treated with first-line osimertinib. Participants may receive osimertinib combined with chemotherapy or other treatment regimens initiated after January 1, 2024, or osimertinib alone as monotherapy for newly diagnosed metastatic NSCLC. About 30% of patients enrolling before starting osimertinib will have imaging done at set intervals to monitor disease progression. Treatments are given as part of routine clinical care without experimental procedures. Throughout the study, data will be collected at baseline, during treatment, and at therapy discontinuation. Researchers will assess progression-free survival, overall survival, and time to stopping treatment, tracking these outcomes up to 100 months from treatment start. Participants are observed in a real-world setting, with no investigational drugs administered, and the study will continue until April 2029.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.
1-10 of 15
1